Cell cycle dependent antagonistic interactions between paclitaxel and carboplatin in combination therapy

Cancer Biology and Therapy

Volumn 6, Issue 7, 2007, Pages 1067-1073

  Xiong, Xiaoxiong ^a   Sui, Meihua ^b   Fan, Weimin ^b   Kraft, Andrew S ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Apoptosis; Cell cycle arrest; Combination therapy; Drug interaction; Paclitaxel

Indexed keywords

CARBOPLATIN; PACLITAXEL;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG CYTOTOXICITY; DRUG EXPOSURE; FEMALE; HUMAN; HUMAN CELL; MITOSIS INHIBITION; OVARY CANCER; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION;

EID: 42449130976     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.6.7.4323     Document Type: Article

References (36)

1. Gogas H, Fountzilas G. The role of taxanes as a component of neoadjuvant chemotherapy for breast cancer. Ann Oncol 2003; 4:667-74.
2. Ghamande S, Lele S, Marchetti D, Baker T, Odunsi K. Weekly paclitaxel in patients with recurrent or persistent advanced ovarian cancer. Int J Gynecol Cancer 2003; 13:142-7.
3. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. Nature 1979; 277:665-7.
4. Schiff PB, Horwitz SB. Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci USA 1980; 77:1561-5.
5. Cheng L, Zheng S, Raghunathan K, Prist DG, Willingham MC, Norris JS, Fan W. Characterizations of taxol-induced apoptosis and altered gene expression in human breast cancer cells. Cell Pharmacol 1995; 2:249-57.
6. Fan W. Possible mechanisms of paclitaxel-induced apoptosis. Biochem Pharmacol 1999; 57:1215-21.
7. Pentheroudakis G, Razis E, Athanassiadis A, Pavlidis N, Fountzilas G. Paclitaxel-carboplatin combination chemotherapy in advanced breast cancer: Accumulating evidence for synergy, efficacy, and safety. Med Oncol 2006; 23:147-60.
8. Pinto AL, Lippard SJ. Sequence-dependent termination of in vitro DNA synthesis by cis- and trans- diamminedichloroplatinum. PNAS 1985; 82:4616-9.
9. Jamieson ER, Lippard SJ. Structure, recognition, and processing of cisplatin-DNA adducts. Chemical Reviews 99:2467-98.
10. van der Vijgh WJ. Clinical pharmacokinetics of carboplatin. Clin Pharmacokinet 1991; 21:242-61.
11. Ozols RF, et al. Gynecologic oncology Group: Phase III trial of carboplatin and paclitaxel compare with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic oncology group study. J Clin Oncol 2003; 21:3194-200.
12. Hensley ML, Correa DD, Thaler H, Wilton A, Venkatramen E, Sabbatin P. Chi DS, Dupont J, Spriqqs D, Aghajanian C. Phase I/II study of weekly paclitaxel plus carboplatin and gemcitabine as first line treatment of advanced-stage ovarian cancer: Pathologic complete response and longitudinal assessment of impact on cognitive functioning. Gynecologic Oncol 2006; 102:270-7.
13. Pentheroudakis G, Razis E, Athanassiadis A, Pavlidis N, Fountzilas G. Paclitaxel-carboplatin combination chemotherapy in advanced breast cancer: Accumulating evidence for synergy, efficacy, and safety. Med Oncol 2006; 23:147-60.
14. Markman M, Elson P, Kulp B, Peterson G, Zanotti K, Webster K, Belinson J. Carboplatin plus paclitaxel combination chemotherapy: Impact of sequence of drug administration on treatment-induced neutropenia. Gynecol Oncol 2003; 91:118-22.
15. Chou TC. Derivation and properties of Michaelis-Menten type and Hill type equations for reference ligands. J Theoretical Biol 1976; 7:253-76.
16. Sui M, Xoing X, Kraft A, Fan W. Combination of gemcitabine antagonizes antitumor activity of paclitaxel through prevention of mitotic arrest and apoptosis. Cancer Biol Ther 2006; 5:1015-21.
17. Zeng S, Chen YZ, Fu L, Johnson KR, Fan W. In vitro evaluation of schedule-dependent interactions between docetaxel and doxorubicin against human breast and ovarian cancer cells. Clin Cancer Res 2000; 6:3766-73.
18. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 1991; 139:271-9.
19. Haldar S, Chintapalli J, Croce CM. Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res 1996; 56:1253-5.
20. Sui M, Dziadyk JM, Zhu X, Fan W. Cell cycle-dependent antagonistic interactions between paclitaxel and gamma-radiation in combination therapy. Clin Cancer Res 2004; 10:4848-57.
21. Huang Y, Johnson KR, Norris JS, Fan W. Nuclear factor-kappa B/I kappa B signaling pathway may contribute to the mediation of paclitaxel-induced apoptosis in solid tumor cells. Cancer Res 2000; 60:4426-32.
22. Huang Y, Fan W. IκB kinase activation is involved in regulation of paclitaxel-induced apoptosis in human tumor cell lines. Mol Pharmacol 2002; 61:105-13.
23. Blagosklonny MV, Schulte T, Nguyen P, Trepel J, Neckers LM. Taxol-induced apoptosis and phosphorylation of bcl-2 protein involves c-raf-1 signal transduction pathway. Cancer Res 1996; 56:1851-4.
24. Izbicka E, Campos D, Carrizales G, Patnaik A. Biomarkers of anticancer activity of R115777 (Tipifarnib, Zarnestra) in human breast cancer models in vitro. Anticancer Res 2005; 25:3215-23.
25. Devita VT. Principles of chemotherapy. In: Devita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. 4th ed. Philadelphia, PA: J. B. Lippincott Co., 1993:276-92.
26. Rideout DC, Chou TC. Synergism, antagonism, and potentiation in chemotherapy: An overview. In: Chou TC, Rideout DC, eds. Synergism and Antagonism in Chemotherapy. San Diego, CA: Academic Press, 1997:3-60.
27. Bertino JR, Chou TC. Chemotherapy: Synergism and antagonism. In: Bertino JR, ed. Encyclopedia of Cancer. San Diego, CA: Academic Press, 1997:368-79.
28. Shin DM, Lippman SM. Paclitaxel-based chemotherapy for recurrent and/or metastatic head and neck squamous cell carcinoma: Current and future directions. Semin Oncol 1999; 26:100-5.
29. Huizing MT, Giaccone G, van Warmerdam LJ, et al. Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer. Journal of Clin Onc 1997; 15:317-29.
30. Rowinksy EK, Gilbert MR, McGuire WP, et al. Sequences of taxol and cisplatin: A phase I and pharmacologic study. Journal Clin Onc 1991; 9:1692-703.
31. Sovak MA, Lutzker S, Zheng L. Rational drug sequencing of paclitaxel, gemcitabine and carboplatin in patients with untreated stage IV and select stage IIIB nons-mall cell lung cancer. Lung Cancer 2006; 53:177-81.
32. Johnson KR, Wang L, Miller IIIrd MC, Willingham MC, Fan W. 5-Fluorouracil interferes with paclitaxel cytotoxicity against human solid tumor cells. Clin Cancer Res 1997; 3:1739-45.
33. Johnson KR, Young KK, Fan W. Antagonistic interplay between antimitotic and G1-S arresting agents observed in experimental combination therapy. Clin Cancer Res 1999; 5:2559-65.
34. The International Collaborative Ovarian Neoplasm (ICON) Group. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: The ICON3 randomised trial. Lancet 2002; 360:505-15.
35. Muggia FM. Sequential single agents as first-line chemotherapy for ovarian cancer: A strategy derived from the results of GOG-132. Int J Gynecol Cancer 2003; 13:156-62.
36. Cheng SCS, Luo D, Xie Y. Taxol induced Bcl-2 protein phosphorylation in human hepatocellular carcinoma QGY-7703 cell line. Cell Biol Int 2001; 25:261-5.